• Home
  • >
  • Bliss Gvs Pharma Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/bliss-gvs-pharma-ltd.png Logo

Bliss Gvs Pharma Ltd Financial Statement

Bliss Gvs Pharma Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Mar 2024Dec 2023Sep 2023
Revenue172.28169.23181.93
Operating Expense179.75132.67129.01
Net Profit-11.4620.7233.89
Net Profit Margin-6.6512.2418.63
Earning Per Share-1.111.993.25
EBIDTA2.2935.1852.8
Effective Tax Rate-80.1917.5622.77

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Bliss Gvs Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual751.59747.45577.21
Operating Expenses Annual634.27629.11470.56
Operating Profit Annual135.1176.24126.87
Interest Annual10.364.745.51
Depreciation18.6717.3317.23
Net Profit Annual70.8615.0468.49
Tax Annual29.3431.0430.16

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Bliss Gvs Pharma Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning21.9913.1315.34
Cash Flow from Operations34.31135.4863.97
Cash Flow from Investing-6.36-102.9-45.38
Cash Flow from Financing-24.94-23.73-20.8
Cash Flow at the End25.0121.9913.13

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Bliss Gvs Pharma Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)17.9820.0421.98
PBIT Margin (%)15.4917.7218.99
PBT Margin (%)13.6113.3314.72
Net PROFIT Margin (%)14.2914.5614.5
Return On Networth / Equity (%)9.015.359.58
Return On Networth /Employed(%)12.1414.2312.2
Return On Assets (%)10.8611.369.14
Total Debt / Equity(X)0.10.110.13
Asset Turnover Ratio (%)0.760.780.63

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Bliss Gvs Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual378.05280.76233.72
Total Current Assets Annual697.37776.86765.2
Non Current Assets Annual459.49331.89311.59
Total Shareholders Funds Annual883.9818.7808.25
Total Assets Annual1,156.851,108.751,076.79

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Bliss Gvs Pharma Ltd Earning Calls
Mar 2024
EPS beaten by 1.15 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Bliss Gvs Pharma Ltd has a market capitalization of 1,179.34 Cr. Value Research classifies it as a Small-Cap company.

Yes, Bliss Gvs Pharma Ltd is debt-free with a debt-to-equity ratio of 0.10.

In FY 2023, Bliss Gvs Pharma Ltd recorded a total revenue of approximately 770.24 Cr marking a significant milestone in the company's financial performance.

Bliss Gvs Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.0% annually, respectively..

Bliss Gvs Pharma Ltd's current PE ratio is 15.63.

Bliss Gvs Pharma Ltd's ROCE averaged 13.5% from the FY ending March 2022 to 2024, with a median of 14.3%. It peaked at 14.3% in March 2024, reflecting strong capital efficiency over the period..

Bliss Gvs Pharma Ltd's latest EBIT is Rs. 123.78 Cr, surpassing the average EBIT of Rs. 99.71 Cr over the 5 years..